Q4 2024 Earnings Forecast for Alimera Sciences, Inc. Issued By HC Wainwright (NASDAQ:ALIM)

Alimera Sciences, Inc. (NASDAQ:ALIM – Get Rating) – Investment analysts at HC Wainwright dropped their Q4 2024 earnings per share estimates for Alimera Sciences in a research note issued to investors on Friday, May 19th. HC Wainwright analyst Y. Chen now anticipates that the biopharmaceutical company will earn $0.17 per share for the quarter, down from their previous forecast of $0.22. The consensus estimate for Alimera Sciences’ current full-year earnings is ($1.19) per share.

Several other research analysts have also commented on the stock. Craig Hallum decreased their price objective on shares of Alimera Sciences from $18.00 to $8.00 in a report on Monday, April 3rd. StockNews.com initiated coverage on shares of Alimera Sciences in a report on Tuesday, May 16th. They issued a “hold” rating for the company.

Alimera Sciences Trading Down 6.5 %

Alimera Sciences stock opened at $2.30 on Monday. The firm has a 50-day moving average of $1.87 and a 200-day moving average of $2.59. The firm has a market cap of $17.02 million, a P/E ratio of -0.94 and a beta of 1.38. Alimera Sciences has a 1-year low of $1.30 and a 1-year high of $7.92.

Insider Buying and Selling at Alimera Sciences

In other Alimera Sciences news, major shareholder Alto Investors Lp Palo sold 200,919 shares of the company’s stock in a transaction that occurred on Friday, March 24th. The shares were sold at an average price of $1.56, for a total transaction of $313,433.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Alimera Sciences news, Director Adam Morgan bought 1,401,901 shares of the business’s stock in a transaction that occurred on Wednesday, May 17th. The stock was purchased at an average price of $1.70 per share, for a total transaction of $2,383,231.70. Following the completion of the transaction, the director now owns 1,659,654 shares of the company’s stock, valued at approximately $2,821,411.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Alto Investors Lp Palo sold 200,919 shares of the stock in a transaction dated Friday, March 24th. The stock was sold at an average price of $1.56, for a total value of $313,433.64. The disclosure for this sale can be found here. 12.90% of the stock is owned by corporate insiders.

Institutional Trading of Alimera Sciences

Institutional investors and hedge funds have recently bought and sold shares of the stock. Millennium Management LLC purchased a new position in Alimera Sciences in the fourth quarter worth about $32,000. Susquehanna International Group LLP purchased a new position in Alimera Sciences in the fourth quarter worth about $92,000. Renaissance Technologies LLC boosted its stake in Alimera Sciences by 2.3% during the second quarter. Renaissance Technologies LLC now owns 127,693 shares of the biopharmaceutical company’s stock worth $698,000 after buying an additional 2,900 shares during the period. Finally, Caligan Partners LP purchased a new position in Alimera Sciences during the fourth quarter worth $1,297,000. 24.58% of the stock is currently owned by institutional investors.

About Alimera Sciences

(Get Rating)

Alimera Sciences, Inc engages in the research and development of biopharmaceutical products. It operates through the following geographical segments: U.S. and International. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration and retinal vein occlusion.